Empagliflozin; Metformin Hydrochloride Patents

Given below is the list of patents protecting Empagliflozin; Metformin Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.

A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Empagliflozin; Metformin Hydrochloride's patents.

Latest Legal Activities on Empagliflozin; Metformin Hydrochloride's Patents

Given below is the list recent legal activities going on the following patents of Empagliflozin; Metformin Hydrochloride.

Activity	Date	Patent Number
Critical Events This Week
Payment of Maintenance Fee, 4th Year, Large Entity	27 Sep, 2023	US10610489
Payment of Maintenance Fee, 4th Year, Large Entity	13 Sep, 2023	US10596120
Recordation of Patent Grant Mailed Critical	07 Apr, 2020	US10610489
Patent Issue Date Used in PTA Calculation Critical	07 Apr, 2020	US10610489
Recordation of Patent Grant Mailed Critical	24 Mar, 2020	US10596120
Patent Issue Date Used in PTA Calculation Critical	24 Mar, 2020	US10596120
Email Notification Critical	19 Mar, 2020	US10610489
Issue Notification Mailed Critical	18 Mar, 2020	US10610489
Correspondence Address Change Critical	12 Mar, 2020	US10596120
Dispatch to FDC	05 Mar, 2020	US10610489